Discover an informative webinar in which the first results from the Bio-Hermes-001 study are discussed.
The Bio-Hermes study compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays. It revealed a strong correlation between several blood tests, particularly p-tau 217, with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease.
In this webinar, experts in the field will discuss what the impact is for people who are living with the disease now and in the near future, in addition to implications for Physicians and Researchers in the field. They will also focus on how the Bio-Hermes study will help in the diagnosis of Alzheimer’s disease and improve clinical trial enrollment.
Register for this webinar today to gain insights about the Bio-Hermes-001 study and the correlation between blood biomarkers and the presence of amyloid plaques in Alzheimer’s disease.
Speakers
Dr. Diana Kerwin, Founder & President, Kerwin Medical Center and PI for Bio-Hermes-001
Bio coming soon.
Message Presenter
Dr. Allen Levey, Robert W. Woodruff Professor and Director of the Goizueta Alzheimer’s Disease Research Center
Dr. Allan Levey is the Robert W. Woodruff Professor and Director of the Goizueta Alzheimer’s Disease Research Center and the Goizueta Institute at Emory University. Dr. Levey received a BS from University of Michigan and an MD and PhD (Immunology) from the University of Chicago.
He then trained in neurology at Johns Hopkins and joined their faculty prior to moving to Emory in 1991. He chaired the Emory Department of Neurology from 2003-2021, leading it to be among the top NIH-funded research departments with a major expansion of the faculty and the clinical and educational programs.
Read more...
He leads multi-institutional teams in NIH translational programs, including Accelerating Medicine Partnership for Alzheimer’s Disease and the TREAT-AD consortia, and he is a steering committee member for the AD clinical trials programs. His research has produced more than 500 publications with 50,000+ citations and an H index of 122, funded by grants from the NIH totaling more than $125 million. He has received numerous awards and is a member of the National Academy of Medicine.
Read Less...
Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University School of Medicine
Dr. Suzanne Schindler is a Clinical Neurologist and Neuroscientist focused on improving the diagnosis and treatment of Alzheimer’s disease. She completed her MD/PhD program, a neurology residency and a Fellowship in Dementia at Washington University. Dr. Schindler sees patients with memory concerns and coordinates biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center. Her research is focused on the clinical validation of blood tests for Alzheimer’s disease.
Message PresenterWho Should Attend?
This webinar will appeal to professionals in the following fields:
- Alzheimer’s researchers
- Alzheimer’s drug development leadership
What You Will Learn
Attendees will learn about:
- Impact for people who are living with Alzheimer’s disease now and in the near future
- How to improve Alzheimer’s diagnoses and clinical trial enrollment
Xtalks Partner
Global Alzheimer’s Platform Foundation
The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric, non-profit organization dedicated to speeding the delivery of innovative therapies to those living with Alzheimer’s and Parkinson’s by reducing the time and cost of Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account